Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715726 | 0.93 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL715725 | 0.93 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL715724 | 0.93 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL702970 | 0.81 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL702971 | 0.81 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL704402 | 0.81 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL704596 | 0.78 | HSD11B1 (0.53) | HSD11B1 | |
| SCHEMBL75933 | 0.72 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL75607 | 0.72 | HSD11B1 (0.42) | HSD11B1 | |
| SCHEMBL4524988 | 0.70 | HSD11B1 (0.53) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124636-B2 | Imidazolidinone derivatives as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HSD11B1, HSD17B1, HSD17B11 | HSD11B1 1/4885TDP1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.